SCHEMBL294423

SCHEMBL294423

CCC(O)c1ccncc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.60
CYP3A4 P08684 2/20 0.43
CYP2C19 P33261 1/20 0.43
CYP51A1 Q16850 2/20 0.42
CYP17A1 P05093 4/20 0.42
PGR P06401 1/20 0.41
CYP19A1 P11511 2/20 0.41
CYP11B1 P15538 1/20 0.41
CYP11B2 P19099 1/20 0.41
SLC6A2 P23975 2/20 0.39
SLC6A4 P31645 2/20 0.39
SLC6A3 Q01959 2/20 0.39
HTT P42858 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
ALDH1A1 P00352 1/20 0.38
POLB P06746 1/20 0.38
MAPT P10636 1/20 0.38
KDM4E B2RXH2 1/20 0.37
HSD17B10 Q99714 1/20 0.37
TAAR1 Q96RJ0 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25314645 1.00 LMNA (0.60) LMNACYP3A4CYP2C19CYP51A1CYP17A1
1-(4-Pyridyl)-1-Butanol SCHEMBL4956036 0.82 CYP51A1 (0.43) LMNACYP3A4CYP2C19CYP51A1CYP17A1
1-(4-Pyridyl)-1-Butanol SCHEMBL13909751 0.82 CYP51A1 (0.43) LMNACYP3A4CYP2C19CYP51A1CYP17A1
SCHEMBL1607138 0.82 LMNA (0.75) LMNACYP3A4CYP2C19PGRSLC6A2
1-(4-Pyridyl)-1-Butanol SCHEMBL8606540 0.80 CYP51A1 (0.42) LMNACYP3A4CYP2C19CYP51A1CYP17A1
SCHEMBL9603648 0.79 ALDH1A1 (0.45) CYP3A4CYP2C19CYP51A1ALDH1A1POLB
SCHEMBL348431 0.78 CYP3A4 (0.42) LMNACYP3A4CYP2C19CYP51A1CYP17A1
SCHEMBL3851200 0.78 TAAR1 (0.60) LMNACYP3A4CYP2C19CYP17A1CYP19A1
SCHEMBL1516192 0.78 CYP3A4 (0.42) LMNACYP3A4CYP2C19CYP51A1CYP17A1
SCHEMBL6480804 0.78 CYP3A4 (0.42) LMNACYP3A4CYP2C19CYP51A1CYP17A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 204 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119098207-B Solid catalyst and preparation method of L-ribose 浙江晟格生物科技有限公司 2025-03-18 CN claimed
CN-119098207-A Solid catalyst and preparation method of L-ribose 浙江晟格生物科技有限公司 2024-12-10 CN claimed
CN-118577141-A Anion exchange membrane with photocatalytic anti-pollution performance and preparation method and application thereof 浙江工业大学 2024-09-03 CN claimed
CN-116368601-A Etching composition 富士胶片电子材料美国有限公司 2023-06-30 CN claimed
CN-115286784-A Preparation method of solvent-resistant cross-linked anion exchange membrane 浙江工业大学 2022-11-04 CN claimed
CN-112300379-B Crosslinked polyether reverse demulsifier and preparation method thereof 中海油(天津)油田化工有限公司 2022-10-04 CN claimed
CN-112724757-A Ionomer coating for eliminating surface charge, preparation method thereof and corresponding coating 徐宁 2021-04-30 CN claimed
CN-112300379-A Crosslinked polyether reverse demulsifier and preparation method thereof 中海油(天津)油田化工有限公司 2021-02-02 CN claimed
CN-102137672-A Process for the preparation of substituted pyrimidine derivatives JANSSEN PHARMACEUTICA NV 2011-07-27 CN claimed
EP-0301403-B1 CURING AGENT FOR SYNTHETIC RESINS, COMPOSITIONS CONTAINING THE SAME AND USES OF THEM HOECHST AKTIENGESELLSCHAFT (DE) 1992-07-15 EP claimed
US-4847346-A HYDROXYALKYLPYRIDINE BLOCKED DIISOCYANATES AS CURING AGENTS HOECHST AG (DE) 1989-07-11 US claimed
EP-0301403-A2 Curing agent for synthetic resins, compositions containing the same and uses of them HOECHST AKTIENGESELLSCHAFT (DE) 1989-02-01 EP claimed
US-4360363-A HYDROXYALKYLPYRIDINE, SCRUBBING COMBUSTION ENGINEERING, INC. (US) 1982-11-23 US claimed
CN-122011867-A Ionomer coatings for eliminating surface charge, method for preparing same and corresponding coatings 徐宁 2026-05-12 CN disclosed
US-20260078091-A1 Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer AMGEN INC (US) 2026-03-19 US disclosed
EP-4314155-B1 POLYMER COMPOSITION COMPRISING POLYACRYLIC BLOCK COPOLYMER AND AROMATIC BASED POLYALKYLENEOXIDE AS DISPERSANT BASF SE (DE) 2025-04-09 EP disclosed
EP-0301403-A2 Curing agent for synthetic resins, compositions containing the same and uses of them HOECHST AKTIENGESELLSCHAFT (DE) 1989-02-01 EP disclosed
US-4360363-A HYDROXYALKYLPYRIDINE, SCRUBBING COMBUSTION ENGINEERING, INC. (US) 1982-11-23 US disclosed
US-4029788-A ANTIAMEBIC AGENTS AMERICAN CYANAMID COMPANY (US) 1977-06-14 US disclosed
US-4009087-A N-HETERO AROMATIC, AND SULFOALKYL OR SULFOARYL SULFIDE M&T CHEMICALS INC. (US) 1977-02-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260078091-A1 Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer TP53, HIF1AN, MDM2 LMNA 738/4885CYP3A4 3458/4885CYP2C19 2887/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.